HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents

Area of Science:

• Nephrology
• Virology
• Immunology

Background:

• Hepatitis C virus (HCV) infection is a systemic disease with frequent extrahepatic manifestations, notably nephropathies.
• Cryoglobulinemia, a common HCV-related condition, often presents as membranoproliferative glomerulonephritis in the kidneys.
• Other renal diseases linked to HCV include membranous nephropathy, focal segmental glomerulosclerosis, IgA nephropathy, and fibrillary/immunotactoid glomerulopathy.

Purpose of the Study:

• To review the spectrum of kidney diseases associated with Hepatitis C virus infection.
• To discuss the impact of direct-acting antiviral therapies on HCV-related nephropathies.
• To explore alternative and adjunctive treatment strategies for renal disease in HCV patients.

Main Methods:

• Literature review of studies on HCV infection and its renal manifestations.
• Analysis of treatment outcomes for direct-acting antiviral therapies and B-cell depleting agents.
• Evaluation of immunosuppressive therapies and their limitations in HCV-associated kidney disease.

Main Results:

• Direct-acting antiviral therapies have significantly improved viral clearance rates in HCV patients.
• B-cell depleting agents are effective add-on therapies for renal disease remission when antivirals alone are insufficient.
• Traditional immunosuppressive therapies carry risks of increased HCV replication and liver disease worsening.

Conclusions:

• HCV infection is linked to diverse kidney pathologies, with cryoglobulinemia being a prominent example.
• Antiviral advancements have transformed HCV management, impacting renal outcomes.
• Integrated therapeutic approaches combining antivirals with immunomodulatory agents are crucial for managing complex HCV-related nephropathies.